{
    "data": [
        {
            "id": "4560329",
            "type": "article",
            "attributes": {
                "publishOn": "2022-11-24T03:37:13-05:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1181343095/image_1181343095.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Laboratories: Good Execution And Attractive Valuation",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105455",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "422095",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4560329-abbott-laboratories-good-execution-attractive-valuation"
            }
        },
        {
            "id": "4559383",
            "type": "article",
            "attributes": {
                "publishOn": "2022-11-21T01:01:03-05:00",
                "isLockedPro": false,
                "commentCount": 25,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1181343095/image_1181343095.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Laboratories: Prepare For A Tough 2023",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21702",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "421492",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4559383-abbott-labs-stock-prepare-for-tough-2023"
            }
        },
        {
            "id": "4546964",
            "type": "article",
            "attributes": {
                "publishOn": "2022-10-17T11:26:43-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1181343095/image_1181343095.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Laboratories: Shares Remain Expensive While In A Technical Downtrend Ahead Of Earnings",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106553",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "414712",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4546964-abbott-laboratories-shares-remain-expensive-ahead-of-earnings"
            }
        },
        {
            "id": "4546773",
            "type": "article",
            "attributes": {
                "publishOn": "2022-10-16T11:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2962111/image_2962111.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Is Likely To Beat Q3 Estimates - Here's Why I'm Still Not A Buyer",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104751",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "414541",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4546773-abbott-q3-earnings-beat-estimates-not-buyer"
            }
        },
        {
            "id": "4540550",
            "type": "article",
            "attributes": {
                "publishOn": "2022-09-13T09:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1291967144/image_1291967144.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott's Rough Patch: What Gives?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101378",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "408636",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4540550-abbott-stock-rough-patch-hold"
            }
        },
        {
            "id": "4532435",
            "type": "article",
            "attributes": {
                "publishOn": "2022-08-10T08:49:44-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1325784605/image_1325784605.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Laboratories' Dividend Strength Is Top Notch",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24491",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "386892",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4532435-abbott-labs-dividend-strength-is-top-notch"
            }
        },
        {
            "id": "4529925",
            "type": "article",
            "attributes": {
                "publishOn": "2022-08-04T18:12:46-04:00",
                "isLockedPro": false,
                "commentCount": 21,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1332278260/image_1332278260.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Laboratories: A Lesser Johnson & Johnson?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104751",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "386071",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4529925-abbott-laboratories-a-lesser-johnson-and-johnson"
            }
        },
        {
            "id": "4529515",
            "type": "article",
            "attributes": {
                "publishOn": "2022-08-04T08:15:00-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1181343095/image_1181343095.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Laboratories: An Excellent Wealth Compounder You'll Want To Own",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105703",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "385956",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4529515-abbott-laboratories-stock-excellent-wealth-compounder"
            }
        },
        {
            "id": "4524021",
            "type": "article",
            "attributes": {
                "publishOn": "2022-07-18T15:05:46-04:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1399813281/image_1399813281.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Is Abbott Laboratories Stock A Sell Before Upcoming Earnings? Consider Potential Earnings Miss And Valuations",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "39591",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "383047",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4524021-is-abbott-laboratories-stock-sell-before-earnings"
            }
        },
        {
            "id": "4523767",
            "type": "article",
            "attributes": {
                "publishOn": "2022-07-16T10:34:30-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Stocks To Watch: Earnings Blitz Includes Netflix, Tesla, AT&T, Philip Morris, And Twitter",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68015",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4523767-stocks-to-watch-earnings-blitz-includes-netflix-tesla-at-and-t-philip-morris-and-twitter"
            }
        },
        {
            "id": "4521655",
            "type": "article",
            "attributes": {
                "publishOn": "2022-07-04T11:06:17-04:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1240630725/image_1240630725.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott: Successfully Handled The Infant Formula Crisis",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106588",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "381041",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4521655-abbott-successfully-handled-infant-formula-crisis"
            }
        },
        {
            "id": "4521090",
            "type": "article",
            "attributes": {
                "publishOn": "2022-06-30T02:10:45-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1402717542/image_1402717542.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Finds Support Around $100",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24443",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "380571",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4521090-abbott-stock-finds-support-around-100"
            }
        },
        {
            "id": "4513531",
            "type": "article",
            "attributes": {
                "publishOn": "2022-05-20T18:03:40-04:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1181343095/image_1181343095.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Is A Great Company, But Its Price Makes It Unattractive",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80836",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "374886",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4513531-abbott-is-a-great-company-but-its-price-makes-it-unattractive"
            }
        },
        {
            "id": "4507600",
            "type": "article",
            "attributes": {
                "publishOn": "2022-05-06T08:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/988001976/image_988001976.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott: Solid Conviction Pick",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101378",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "372649",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4507600-abbott-stock-q1-2022-earnings-solid-conviction-pick"
            }
        },
        {
            "id": "4497192",
            "type": "article",
            "attributes": {
                "publishOn": "2022-03-23T09:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1250588875/image_1250588875.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott's Bright Future In Connected Tech",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101378",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "366011",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4497192-abbotts-bright-future-in-connected-tech"
            }
        },
        {
            "id": "4496268",
            "type": "article",
            "attributes": {
                "publishOn": "2022-03-17T16:04:33-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1312649132/image_1312649132.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott: Back Where We Were 12 Months Ago Is Not A Bad Place To Be",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "366013",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4496268-abbott-back-where-we-were-12-months-ago-is-not-a-bad-place-to-be"
            }
        },
        {
            "id": "4492932",
            "type": "article",
            "attributes": {
                "publishOn": "2022-03-04T10:02:29-05:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1181343095/image_1181343095.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott: Closing The Gap On Industry Leader",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104695",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "363948",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4492932-abbott-closing-gap-industry-leader"
            }
        },
        {
            "id": "4481959",
            "type": "article",
            "attributes": {
                "publishOn": "2022-01-27T02:29:15-05:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1363138403/image_1363138403.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Is Getting Tested",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24443",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "358842",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4481959-abbott-q4-earnings-upside-potential-stock-buy"
            }
        },
        {
            "id": "4480992",
            "type": "article",
            "attributes": {
                "publishOn": "2022-01-22T09:57:59-05:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Stocks To Watch: FOMC Meeting, Earnings Rush And Testing Times In Crypto",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68015",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4480992-stocks-to-watch-fomc-meeting-earnings-rush-and-testing-times-in-crypto"
            }
        },
        {
            "id": "4480947",
            "type": "article",
            "attributes": {
                "publishOn": "2022-01-22T02:36:34-05:00",
                "isLockedPro": false,
                "commentCount": 18,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/505029896/image_505029896.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Laboratories: Shelter Your Capital With This SWAN Stock",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105703",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "358143",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4480947-abbott-laboratories-shelter-your-capital-with-this-swan-stock"
            }
        },
        {
            "id": "4480546",
            "type": "article",
            "attributes": {
                "publishOn": "2022-01-20T10:30:00-05:00",
                "isLockedPro": false,
                "commentCount": 12,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1305025665/image_1305025665.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Has Abbott Stock Dropped In January And Is A Rebound Likely?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68315",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "357451",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4480546-abbott-stock-dropped-january-rebound-likely"
            }
        }
    ]
}